KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $54.8 million.

  • Halozyme Therapeutics' Retained Earnings fell 8477.61% to $54.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $54.8 million, marking a year-over-year decrease of 8477.61%. This contributed to the annual value of $54.8 million for FY2025, which is 8477.61% down from last year.
  • As of Q4 2025, Halozyme Therapeutics' Retained Earnings stood at $54.8 million, which was down 8477.61% from $502.1 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Retained Earnings ranged from a high of $502.1 million in Q3 2025 and a low of -$433.7 million during Q1 2021
  • For the 5-year period, Halozyme Therapeutics' Retained Earnings averaged around $119.5 million, with its median value being $115.5 million (2023).
  • Its Retained Earnings has fluctuated over the past 5 years, first soared by 245378.0% in 2023, then plummeted by 8477.61% in 2025.
  • Over the past 5 years, Halozyme Therapeutics' Retained Earnings (Quarter) stood at -$58.9 million in 2021, then surged by 343.1% to $143.2 million in 2022, then tumbled by 36.77% to $90.6 million in 2023, then skyrocketed by 297.43% to $359.9 million in 2024, then tumbled by 84.78% to $54.8 million in 2025.
  • Its last three reported values are $54.8 million in Q4 2025, $502.1 million for Q3 2025, and $361.0 million during Q2 2025.